Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Chanel Claudine de Ruiter & Thomas Rustemeyer. (2022) Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review. Psoriasis: Targets and Therapy 12, pages 99-112.
Read now
Read now
Mark Lebwohl, Ahmed M. Soliman, Hongbo Yang, Jessie Wang, Jonathan Freimark & Lluís Puig. (2022) Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment 33:4, pages 2094-2101.
Read now
Read now
Santhi Mantravadi, Alexis Ogdie & Walter K. Kraft. (2017) Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Review of Clinical Pharmacology 10:8, pages 899-910.
Read now
Read now
Articles from other publishers (32)
Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh & Majed Ali Almasaoud. (2023) Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
Ahmed Safi Vahidy, Faizan Niaz, Samiuddin Tariq, Irtebaat Fatima, Yusra Afzal & Abdulqadir J. Nashwan. (2023) IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials. Clinical Immunology Communications 4, pages 7-22.
Crossref
Crossref
Rachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, Ismail Kasujee, Elisa Martini, Esteban Daudén, Gabriella Fabbrocini, Alexander Zink, Christopher E. M. Griffiths & Matthias Augustin. (2023) Implementing well‐being in the management of psoriasis: An expert recommendation. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
M. N. Ostretsova, E. I. Kasikhina, O. V. Zhukova & A.A-H.M. Al-Hawatmi. (2023) The efficiency of the combination of topical and biological therapy in the treatment of nails psoriasis: a prospective study. Meditsinskiy sovet = Medical Council.
Crossref
Crossref
Yuxiong Jiang, Ying Li, Dawei Huang, Xiaoyuan Zhong, Qian Yu, Yanhua Liang, Lin Dang, Chengzhi Lv, Binjiang Lin, Furen Zhang, Yunsheng Liang, Jiajing Lu & Yuling Shi. (2023) Quality of Life Benefit and Clinical Predictors of Complete Skin Clearance in Psoriasis: A Multicenter, Prospective, Real-World Study. Dermatology 239:5, pages 802-810.
Crossref
Crossref
Samar Abdalhamed Tabra, Salwa Elmorsy abd Elghany, Reham A. Amer, Mohamed H. Fouda & Mohammed Hassan Abu-Zaid. (2022) Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clinical Rheumatology 41:11, pages 3391-3399.
Crossref
Crossref
Vineet Kumar Rai, Debabrata Chanda, Chandan Singh Chanotiya & Narayan Prasad Yadav. (2022) A combination of linalool and linalyl acetate synergistically alleviates imiquimod-induced psoriasis-like skin inflammation in BALB/c mice. Frontiers in Pharmacology 13.
Crossref
Crossref
Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter-Brown, Francine Foss, Larisa Geskin, Lawrence Schwartz, Steven Horwitz, Joan Guitart, John Zic, Youn H. Kim, Gary S. Wood, Madeleine Duvic, Wei Ai, Michael Girardi, Alejandro Gru, Emmanuella Guenova, Emmilia Hodak, Richard Hoppe, Werner Kempf, Ellen Kim, Mary Jo Lechowicz, Pablo Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Mark Pittelkow, H. Miles Prince, Jose Antonio Sanches, Makoto Sugaya, Maarten Vermeer, Jasmine Zain, Robert Knobler, Rudolf Stadler, Martine Bagot & Julia Scarisbrick. (2022) Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 140:5, pages 419-437.
Crossref
Crossref
I. Ee, E. Deprez, A. Egeberg, M. Augustin, C. Conrad, V. Corazza, L. Donati, J. Lambert, R. Lăpădatu, A. Meyer, C. Paul, R. Penzer‐Hick, K. Stephen, J. Zon & A. Bewley. (2021) Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. Journal of the European Academy of Dermatology and Venereology 36:3, pages 403-412.
Crossref
Crossref
J.M. Carrascosa, L. Puig, I. Belinchón Romero, L. Salgado-Boquete, E. del Alcázar, J.J. Andrés Lencina, D. Moreno & P. de la Cueva. (2022) [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. Actas Dermo-Sifiliográficas 113:3, pages T261-T277.
Crossref
Crossref
J.M. Carrascosa, L. Puig, I. Belinchón Romero, L. Salgado-Boquete, E. del Alcázar, J.J. Andrés Lencina, D. Moreno & P. de la Cueva. (2022) Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica». Actas Dermo-Sifiliográficas 113:3, pages 261-277.
Crossref
Crossref
Igor Dykukha, Andreu Schoenenberger, Ismail Kasujee, Ulrich Mrowietz & Reinhard Vonthein. (2022) Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2. Dermatology 238:5, pages 910-918.
Crossref
Crossref
Fernando Valenzuela & Rodrigo Flores. 2022. Textbook of Dermatologic Ultrasound. Textbook of Dermatologic Ultrasound
345
365
.
Mariana Fatima Muaccad Gama Wagner, Thérèse Rachell Theodoro, Carlos D’. Apparecida Santos Machad Filho, Luiza Keiko Matsuka Oyafuso & Maria Aparecida Silva Pinhal. (2021) Extracellular matrix alterations in the skin of patients affected by psoriasis. BMC Molecular and Cell Biology 22:1.
Crossref
Crossref
Sylwia Słuczanowska-Głąbowska, Anna Ziegler-Krawczyk, Kamila Szumilas & Andrzej Pawlik. (2021) Role of Janus Kinase Inhibitors in Therapy of Psoriasis. Journal of Clinical Medicine 10:19, pages 4307.
Crossref
Crossref
Jo Lambert, Jes Birger Hansen, Anne Sohrt & Luis Puig. (2021) Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy 11:4, pages 1265-1275.
Crossref
Crossref
Jill Coghlan, Hongliang He & Anna S. Schwendeman. (2021) Overview of Humira® Biosimilars: Current European Landscape and Future Implications. Journal of Pharmaceutical Sciences 110:4, pages 1572-1582.
Crossref
Crossref
Rhea Singh, Esther A. Balogh & Steven R. Feldman. (2020) Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports 9:4, pages 339-352.
Crossref
Crossref
Daniel Barquero-Orias & María Camila Martínez-Franco. (2020) Principios de psoriasis y enfoque terapéutico en embarazo: revisión de literatura. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica 28:2, pages 148-163.
Crossref
Crossref
Jindra Šmejkalová, Lenka Borská, Květa Hamáková, Lenka Hodačová, Eva Čermáková & Zdeněk Fiala. (2020) Quality of life of patients with psoriasis. Central European Journal of Public Health 28:3, pages 219-225.
Crossref
Crossref
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin & Kim Papp. (2020) Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy 10:3, pages 431-447.
Crossref
Crossref
Ahmed Alalaiwe, Chwan-Fwu Lin, Chien-Yu Hsiao, En-Li Chen, Chien-Yu Lin, Wan-Chen Lien & Jia-You Fang. (2020) Development of flavanone and its derivatives as topical agents against psoriasis: The prediction of therapeutic efficiency through skin permeation evaluation and cell-based assay. International Journal of Pharmaceutics 581, pages 119256.
Crossref
Crossref
J.M. Norlin, K. Nilsson, U. Persson & M. Schmitt‐Egenolf. (2019) Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals. British Journal of Dermatology 182:4, pages 965-973.
Crossref
Crossref
Mark G. Lebwohl, Andrew Blauvelt, Alan Menter, Kim A. Papp, Scott Guenthner, Radhakrishnan Pillai, Robert J. Israel & Abby Jacobson. (2019) Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American Journal of Clinical Dermatology 20:6, pages 863-871.
Crossref
Crossref
Aviad Keren, Amos Gilhar, Yehuda Ullmann, Marina Zlotkin‐Frušić, Yoram Soroka, Abraham J. Domb & Mia Levite. (2019) Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1‐like receptor agonist: Fenoldopam. Immunology 158:3, pages 171-193.
Crossref
Crossref
Janet Fricker. (2019) IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. EMJ Dermatology, pages 2-11.
Crossref
Crossref
Janet Fricker. (2019) IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. EMJ Dermatology, pages 2-11.
Crossref
Crossref
Lieke J. van Vugt, Juul M. P. A. van den Reek, Gerjon Hannink, Marieke J. H. Coenen & Elke M. G. J. de Jong. (2019)
Association of
HLA-C*06:02
Status With Differential Response to Ustekinumab in Patients With Psoriasis
. JAMA Dermatology 155:6, pages 708.
Crossref
Crossref
April W. Armstrong, Kristian Reich, Peter Foley, Chenglong Han, Michael Song, Yaung-Kaung Shen, Yin You & Kim A. Papp. (2018) Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology 20:1, pages 155-164.
Crossref
Crossref
Pavel V. Chernyshov. (2019) The Evolution of Quality of Life Assessment and Use in Dermatology. Dermatology 235:3, pages 167-174.
Crossref
Crossref
Carlos Muñoz‐Santos, Joaquín Sola‐Ortigosa & Antonio Guilabert. (2018) Treatment optimization with secukinumab 150 mg for moderate‐to‐severe psoriasis in clinical practice: a single‐center open‐label 52‐week study. International Journal of Dermatology 57:5, pages 615-617.
Crossref
Crossref
J. AlbrechtS. Gerdes. (2017) Switching expensive drugs with frequently diminishing value. British Journal of Dermatology 177:2, pages 338-339.
Crossref
Crossref